Prior Art Litigation Search in Rome.

A prior art search Rome litigation counsel can rely on has to fit both the capital’s industries and its unusual place in the Italian court map. Rome is the seat of the Italian government and the country’s largest pharmaceutical and life-sciences base, from the Menarini and IRBM plants at Pomezia to a deep aerospace, defence and space cluster built around Leonardo, Telespazio, Thales Alenia Space and the Italian Space Agency. When those patents are asserted, the validity fight is heard by the specialised business court in Rome — and, uniquely, the Court of Rome is also the default forum whenever the defendant is not domiciled in Italy, which pulls a large share of foreign-defendant disputes into the city. PerspireIP builds invalidity-grade searches for the parties challenging those patents before the Italian courts, the Unified Patent Court in Milan and the EPO.

Where a prior art search Rome case is actually heard

Italian patent litigation is funnelled into a small set of specialised business courts, the sezioni specializzate in materia di impresa — the tribunale delle imprese — and Rome runs one of the busiest. Patent infringement and nullity actions in the capital are decided by the Sezione Specializzata in materia di Impresa of the Tribunale di Roma, whose specialist judges handle industrial-property, copyright and corporate disputes. Its territorial reach covers the whole Lazio district, so a claim against a company based anywhere in the region is decided in Rome rather than a local ordinary court.

Venue in Italy generally follows the defendant. Under the ordinary rule of forum rei, an action is brought where the defendant is resident or domiciled, so a claim against a Rome or Lazio company lands before the Tribunale di Roma. For infringement, the plaintiff can also sue where the infringing act took place under the forum commissi delicti rule. That gives a rights-holder some choice, but the accused party’s home base still shapes most of the docket, and Rome’s caseload reflects the pharma, aerospace and public-research employers clustered around it.

The feature that most distinguishes Rome from Milan, Turin or Naples is a rule of last resort. When the defendant has no residence, domicile or elected address in Italy, the forum rei cannot operate, so the action can be brought where the plaintiff is domiciled under the forum actoris. And where neither party is domiciled in Italy, Italian law channels the case to one default venue: the Court of Rome. That makes the Tribunale di Roma the national forum for a whole category of international patent disputes.

For an accused party this rule carries real strategic weight. A foreign company sued in Italy, or two non-Italian parties fighting over the Italian designation of a European patent, may find the validity battle heard in Rome even though neither has any operational link to the city. Cross-border declaratory-judgment strategies — the so-called Italian torpedo actions used to establish non-infringement across several countries — have historically clustered around the Rome and Milan courts for exactly this reason, so the jurisdictional starting point can matter as much as the merits.

Whichever route brings a dispute to the Tribunale di Roma, the validity question is identical — was the asserted claim already disclosed before its priority date? Because Rome so often draws foreign patentees, foreign accused parties and prior art scattered across languages, a prior art search Rome counsel can rely on has to reach patent offices and non-patent sources worldwide. PerspireIP retrieves and dates those references and hands your Italian and European counsel a claim-charted invalidity file that stands up whether the parties are Roman, Milanese or based on another continent.

• Tribunale di Roma, Sezione Specializzata in materia di Impresa — the specialised business court for patent infringement and nullity across the Lazio district
• Forum rei plus forum commissi delicti — venue follows the defendant’s seat, with infringement also actionable where the act occurred
• Default forum for foreign-defendant cases — the Court of Rome takes jurisdiction when the defendant is not domiciled in Italy
• Unified Patent Court, Milan — the separate route for unitary and non-opted-out European patents, sitting in Milan, not Rome

No bifurcation and the court-appointed CTU

Two features of Italian procedure decide how prior art is used in Rome. First, unlike the German model, the Italian court does not bifurcate. Validity and infringement are heard together in one proceeding before the same judges, so an accused party cannot lose on infringement while a separate court slowly weighs validity. The invalidity attack has to be trial-ready from the first defensive brief, which means the prior art must already be found, charted and dated when the case opens rather than developed later.

Second, the Tribunale di Roma almost always appoints a consulente tecnico d’ufficio (CTU) — an independent court expert who assesses novelty, inventive step and sufficiency and files a written report. The parties’ own experts, the consulenti tecnici di parte, respond to it, but the CTU’s technical findings carry great weight with the panel. Much of an Italian patent case is effectively won or lost inside that expert phase, on the strength of the references each side puts before the CTU.

That structure rewards evidentiary discipline over volume. A single closely mapped reference, whose public-availability date is proven to the day, does more before a CTU than a long list of loosely relevant hits. We build searches with that audience in mind: every reference is tied to specific claim elements, its disclosure date is evidenced, and the analysis is written so the court expert can follow the novelty and inventive-step argument without re-doing the work.

Italian nullity: the Article 76 grounds

In Italy a patent is struck down through a nullità (nullity) action, and the grounds are codified in Article 76 of the Italian Industrial Property Code (the Codice della Proprietà Industriale, Legislative Decree No. 30 of 10 February 2005, as amended). Any party with a legitimate interest can bring a standalone nullity action before the Tribunale di Roma, and an accused infringer can also raise invalidity as a counterclaim inside the infringement suit — which, because the court does not bifurcate, is decided in the same proceeding.

The grounds track the core patentability requirements. A patent is null where the invention lacks the requirements of patentability — novelty, inventive step, industrial applicability or lawfulness; where the description is not clear and complete enough for a skilled person to carry the invention out; where the subject-matter extends beyond the content of the application as filed or protection has been unlawfully extended; or where the patent was granted to someone not entitled to it. Italian courts treat this list as the exhaustive set of nullity grounds.

• Lack of novelty — a single prior disclosure that anticipates every feature of the claim
• Lack of inventive step — the claim is obvious over the prior art, usually a combination of references
• Insufficiency of disclosure — the specification does not enable a skilled person to work the invention
• Added matter or unlawful extension — the granted claims reach beyond the application as filed
• Lack of entitlement — the proprietor was not the party entitled to the patent

Of these, novelty and inventive step are the grounds that live or die on prior art, and they are where a search earns its keep. Because the court-appointed CTU weighs the references technically, the quality of the art — how tightly it maps to the claim elements and how firmly its publication date is proven — often settles a Rome nullity case well before final argument.

Rome’s UPC and EPO options sit outside Rome

Italy is a founding member of the Unified Patent Court, but none of the UPC sits in Rome. Italy’s entire UPC presence is in Milan, which hosts a Local Division (open since the court’s June 2023 launch) and, since June 2024, a section of the Central Division. So for a unitary patent or a non-opted-out European patent asserted against a Rome party, the choice is between the national Impresa court in Rome and the UPC in Milan — a Rome dispute can be revoked centrally, but only by travelling to the Milan bench, never a Roman one.

What the Milan Central Division section hears is fixed by technology. When the United Kingdom left the UPC, the competences of the former London section were redistributed, and Milan took IPC section A (human necessities), excluding Supplementary Protection Certificates. Revocations of SPCs and their basic patents go to Paris, while chemistry and mechanical-engineering revocations sit in Munich. Given Rome’s pharma weight, many life-sciences revocations map to the Milan section — but the SPC carve-out means a Rome party must check whether a Paris filing is required first.

There is also the central attack the national courts cannot offer. Most valuable patents asserted in Rome arrive as European patents validated in Italy, and within nine months of grant anyone can file an opposition at the EPO. A successful opposition revokes the patent in every validated state at once, Italy included, on the same novelty, inventive-step, added-matter and sufficiency grounds. Where that window is still open, one rigorous prior art search can feed an EPO opposition, a Tribunale di Roma nullity action and a UPC revocation together, so the same references do double or triple duty.

Pharma and life-sciences prior art in the capital

Rome and the surrounding Lazio region form Italy’s densest pharmaceutical and life-sciences base. The Menarini group manufactures biologics at Pomezia, south of Rome; the IRBM research campus and its Advaxia Biologics arm run vaccine and gene-therapy development in the same corridor; and a broad tier of contract manufacturers, generics producers and biotech firms sits across the region. When those portfolios are asserted — over active compounds, formulations, dosage regimens, antibodies or manufacturing processes — the accused generic or biosimilar maker has to knock out the claim, often against a tight regulatory launch clock.

Life-sciences validity work has its own centre of gravity. The decisive prior art is frequently non-patent literature: journal articles, clinical-trial registries and results, conference abstracts, pharmacopoeia monographs and regulatory disclosures that never surfaced during examination. Public-availability dating is often the hardest-fought point, because whether a conference abstract or a trial record counts as prior art can turn on a single publication date. For second-medical-use and selection-invention claims, the inventive-step analysis over that literature is usually where the case is decided.

The regulatory clock shapes the strategy. A generic or biosimilar entrant usually wants clearance before launch, so the invalidity search has to be finished and defensible ahead of the marketing-authorisation timetable, not after the assertion lands. We therefore prioritise the references most likely to sway a court-appointed CTU on novelty and inventive step, and we document the public-availability date of each clinical abstract, poster, thesis or trial record to the standard a Rome nullity action demands. In a field where the same disclosure can appear years before grant in a conference programme, that dating discipline is often the whole case.

Supplementary Protection Certificates add a further layer. An SPC extends protection for a medicinal product beyond the basic patent’s term, and challenging one means attacking the underlying patent or the certificate’s own conditions — and, at the UPC, routing SPC revocations to Paris rather than Milan. We scope pharma searches to that reality, mining chemical, biological and clinical databases alongside the patent literature and dating every reference so it survives the CTU’s scrutiny in a Rome nullity action or a central revocation abroad.

Aerospace, defence and space: Rome’s second patent frontier

Rome is the command centre of Italy’s aerospace, defence and space industry. Leonardo, one of the world’s largest defence and aerospace groups, is headquartered in the city; Telespazio, its satellite-services joint venture with Thales, is also Rome-based; Thales Alenia Space engineers spacecraft and payloads in Italy; and the Italian Space Agency (ASI) sits in Rome alongside public research bodies such as the CNR and ENEA. That concentration produces dense, highly technical patents — radar and avionics, satellite payloads, propulsion, secure communications, advanced materials and additive manufacturing.

Patent disputes in this world look nothing like consumer litigation. Many of the assertions are between large primes and their suppliers, and the subject-matter is often dual-use, spanning civil and defence applications. A supplier or competitor sued over a widely used technique — a signal-processing method, an antenna architecture, a thermal-protection material — has to show the claimed invention was already public at its priority date, frequently against a patentee with deep in-house R&D records.

Invalidity work here leans heavily on grey literature and standards. The strongest reference is often a conference paper, a space-agency or defence technical report, an academic thesis, a standards document from bodies like ECSS or ETSI, or archived project documentation whose exact publication date decides whether it is prior art at all. Proving public availability — not merely finding the disclosure — is the hardest-fought issue, and it is the core of how we build an aerospace or defence invalidity case for a Rome forum, the UPC or the EPO.

How PerspireIP builds a Rome invalidity search

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date printed on the cover. For pharma and life-sciences assertions we combine patent searching with deep retrieval across chemical, biological, clinical-trial and regulatory sources; for aerospace and defence we add engineering standards, space-agency and defence technical reports, conference proceedings, theses and archived documentation — and in either field we date every reference to the day.

• Claim charting mapped to novelty and inventive step under Article 76 of the Italian Industrial Property Code and the EPC
• Deep non-patent retrieval across life-sciences, clinical, standards, aerospace and academic sources, in multiple languages
• Public-availability dating for every reference, evidenced for journals, conference papers, trial records and online disclosures alike
• Prior art scoped to your forum — a Tribunale di Roma nullity action, a UPC revocation in Milan or Paris, or the nine-month EPO opposition window
• A written invalidity analysis and reference packages ready for the court-appointed CTU, the UPC panel or the EPO

Speed matters as much as depth. Because the Italian court expects the invalidity case to be trial-ready and the EPO opposition window closes nine months after grant, we run patent and non-patent retrieval in parallel and report interim findings early, so counsel can choose between a Rome nullity action, a UPC revocation and an EPO opposition while every option is still open. When a single European patent is challenged on several fronts at once, we build one master reference set and tailor the claim charts to each forum, so an opposition, a Tribunale di Roma nullity defence and a Milan revocation all draw on the same proven prior art.

Because Rome so often draws foreign-defendant and cross-border cases, we are used to working with international patentees, multi-jurisdiction art and non-Italian counsel, and we deliver a file that reads the same to a Roman panel as to a UPC bench. We act as a specialist search partner alongside your Italian and European lawyers, work to Impresa-court, UPC and EPO deadlines, and keep every engagement confidential.

Whether you are a generics or biosimilar maker facing a pharma assertion, an aerospace or defence contractor challenging a competitor’s patent, or litigation counsel preparing a nullity defence before the Tribunale di Roma, we scale to fit — a single search, a multi-patent campaign or ongoing portfolio support. Send us the patent number and your key dates, and we will scope a prior art search Rome project within one business day.

IP Landscape & Resources in Rome

Key intellectual-property authorities and venues relevant to Rome:

• UIBM (Ufficio Italiano Brevetti e Marchi) — the Italian Patent and Trademark Office, which grants Italian national patents challengeable only before the Italian courts
• Unified Patent Court — the UPC, whose Milan Local Division and Central Division section hear revocation actions on unitary and non-opted-out European patents affecting Italy
• European Patent Office (EPO) — grants European patents validated in Italy and runs post-grant opposition, a central attack filed within nine months of grant
• Italian Industrial Property Code (WIPO Lex) — Legislative Decree No. 30 of 2005, whose Article 76 sets the grounds for Italian patent nullity, including lack of novelty and inventive step

Request a Prior Art Search in Rome

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions